Aimmune Therapeutics presented new data on the company’s AR101 peanut allergy therapy as well as a real-world data study at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
The U.S. Food and Drug Administration accepted for review the Biologics License Application (BLA) for DBV Technologies’ investigational Viaskin Peanut immunotherapy for the treatment of peanut-allergic children ages 4 to 11 years.
Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.
A U.S. Food and Drug Administration advisory panel recommended approving the first therapy for peanut allergies, which affect over 1.6 million children in the United States, despite raising concerns about the risk of severe allergic reactions Palforzia poses to young patients.
After an eight month delay, France-based DBV Technologies announced the resubmission of a Biologics License Application to the U.S. FDA for the non-invasive allergy patch Viaskin Peanut.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.
EpiPens and other autoinjectors filled with epinephrine to treat severe allergic reactions may still be potent enough to work many months past their labeled expiration date, according to a study that concludes patients might need expensive refills less often.
Almost three in four U.S. allergy specialists are prescribing tablets to ease symptoms caused by pollen, ragweed and dust at least some of the time, though they have not completely shifted away from allergy shots, a survey suggests.
Aimmune Therapeutics announced that the Brisbane, Calif.-based company’s Phase III European clinical trial of AR101 for the treatment of peanut allergy met the primary efficacy endpoint.
IQVIA’s FluSTAR Online Dynamic Platform Helps Consumers Track Local Rates of Flu, Allergy and Asthma
IQVIA – a leader in human data science – provides consumers with quick and easy access to seasonal suffering data, giving them unique insights into important health related information. Recent data show that flu season is hitting hard in several key markets.